STOCK TITAN
  1. Home
  2. Sec-filings
  3. BIIB
  4. [8-K] BIOGEN INC. Reports Material Event

Biogen (NASDAQ: BIIB) posts 2026 director and proposal vote tallies

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Biogen Inc. reported the voting results from its 2026 Annual Meeting of Stockholders held on June 9, 2026. Stockholders voted on the election of directors and other proposals. Director nominees, including Christopher A. Viehbacher and Lloyd Minor, each received substantially more votes "For" than "Against," with notable support such as 121,127,966 votes "For" for Mr. Viehbacher and 121,220,738 votes "For" for Dr. Minor. One proposal received 124,551,887 votes "For" versus 6,627,086 "Against," while another proposal received 114,184,816 votes "For" and 7,454,737 "Against," along with broker non-votes.

Positive

  • None.

Negative

  • None.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Votes for Lloyd Minor 121,220,738 votes Director election at 2026 Annual Meeting
Votes for Christopher A. Viehbacher 121,127,966 votes Director election at 2026 Annual Meeting
Proposal vote – For 124,551,887 votes One meeting proposal with 6,627,086 Against and 87,576 abstentions
Proposal vote – For with broker non-votes 114,184,816 votes Another proposal with 7,454,737 Against, 267,869 abstentions, 9,359,127 broker non-votes
Broker non-votes on proposal 9,359,127 shares Recorded on a proposal at the 2026 Annual Meeting
Annual Meeting of Stockholders financial
"On June 9, 2026, Biogen Inc. held its 2026 Annual Meeting of Stockholders."
Broker Non-Votes financial
"Broker Non-Votes 9,359,127"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
Emerging growth company regulatory
"Emerging growth company On June 9, 2026, Biogen Inc."
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
false 0000875045 0000875045 2026-06-09 2026-06-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 9, 2026

 

 

Biogen Inc.

(Exact name of registrant as specified in its charter)

 

Delaware 0-19311 33-0112644
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

 

225 Binney Street, Cambridge, Massachusetts 02142

(Address of principal executive offices; Zip Code)

 

Registrant’s telephone number, including area code: (617) 679-2000

 

Not Applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.0005 par value per share BIIB The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

¨ Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 
 

 

 

Item 5.07Submission of Matters to a Vote of Security Holders

 

On June 9, 2026, Biogen Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders. The final voting results for this meeting are as follows:

 

1.Stockholders elected ten nominees to the Board of Directors to serve for a one-year term extending until the 2027 annual meeting of stockholders and their successors are duly elected and qualified, with the votes cast as follows:

 

Nominee   Votes For   Votes Against   Abstentions   Broker Non-Votes
Maria C. Freire  

103,033,121 

    

18,790,237 

    

84,064 

    

9,359,127 

  
William A. Hawkins  

102,135,204 

    

19,683,098 

    

89,120 

    

9,359,127 

  
Susan K. Langer  

103,931,406 

    

17,886,544 

    

89,472 

    

9,359,127 

  
Jesus B. Mantas  

101,698,187 

    

20,117,077 

    

92,158 

    

9,359,127 

  
Lloyd Minor  

121,220,738 

    

594,000 

    

92,684 

    

9,359,127 

  
Menelas Pangalos  

121,130,060 

    

682,983 

    

94,379 

    

9,359,127 

  
Monish Patolawala  

120,796,249 

    

1,016,057 

    

95,116 

    

9,359,127 

  
Eric K. Rowinsky  

93,569,685 

    

28,216,589 

    

121,148 

    

9,359,127 

  
Stephen A. Sherwin  

103,025,923 

    

18,788,272 

    

93,227 

    

9,359,127 

  
Christopher A. Viehbacher  

121,127,966 

    

688,051 

    

91,405 

    

9,359,127 

  

 

2.Stockholders ratified the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with the votes cast as follows:

  

 

Votes For   Votes Against   Abstentions  
124,551,887   6,627,086   87,576  

 

3.Stockholders approved the advisory vote on executive compensation, with the votes cast as follows:

 

 

Votes For   Votes Against   Abstentions   Broker Non-Votes
114,184,816   7,454,737   267,869  

9,359,127 

 

 

 

 
 

 

 

Signatures

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

  Biogen Inc.  
     
     
  By: /s/ Wendell Taylor  
    Wendell Taylor  
    Secretary  
Date: June 10, 2026        

 

 

 

Source: View Original Filing on SEC EDGAR

FAQ

What did Biogen (BIIB) disclose in its latest 8-K filing?

Biogen disclosed the final voting results from its 2026 Annual Meeting of Stockholders. The filing details how shareholders voted on director elections and other proposals, including specific "For," "Against," "Abstain," and broker non-vote tallies for each item.

How did Biogen (BIIB) shareholders vote on director nominees in 2026?

Biogen shareholders gave strong support to all listed director nominees, with each receiving more votes "For" than "Against." For example, Christopher A. Viehbacher received 121,127,966 votes "For" and 688,051 "Against," while Lloyd Minor received 121,220,738 "For" and 594,000 "Against."

What were the total vote counts on one key Biogen (BIIB) proposal?

One proposal at Biogen’s 2026 Annual Meeting received 124,551,887 votes "For," 6,627,086 votes "Against," and 87,576 abstentions. These figures show a significantly higher number of affirmative votes than opposing votes among shares present and entitled to vote.

Did any Biogen (BIIB) proposal include broker non-votes in 2026?

Yes. One proposal recorded 114,184,816 votes "For," 7,454,737 "Against," 267,869 abstentions, and 9,359,127 broker non-votes. Broker non-votes generally arise when intermediaries lack discretion to vote uninstructed shares on certain matters presented to shareholders.

Where was Biogen’s 2026 Annual Meeting information recorded?

The 2026 Annual Meeting voting results were recorded in a current report on Form 8-K. This report lists director nominees, their respective vote totals, and the vote counts for other proposals considered by Biogen stockholders at the meeting.

Filing Exhibits & Attachments

3 documents

Other Documents